Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Combined Modality Therapy
Doxorubicin
/ administration & dosage
Female
Humans
Male
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Retrospective Studies
Soft Tissue Neoplasms
/ drug therapy
Treatment Outcome
Doxorubicin
Hyperthermia
Olaratumab
Platelet-derived growth factor receptor alpha (PDGFRA)
Soft tissue sarcoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Jan 2020
29 Jan 2020
Historique:
received:
01
12
2019
accepted:
16
01
2020
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
29
9
2020
Statut:
epublish
Résumé
The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, recently the phase III ANNOUNCE trial could not confirm the additional value of olaratumab in this context. Here, in a retrospective analysis we share our single-centre experience with olaratumab/doxorubicin in STS by including n = 32 patients treated with olaratumab/doxorubicin between 2016 and 2019. Median progression-free survival (PFS) in the overall cohort was 3.1 months (range 0.6-16.2). A response [complete remission (CR), partial remission (PR) or stable disease (SD)] was seen in n = 11 (34%) cases, whereas n = 21 (66%) patients showed progressive disease (PD). In n = 9 patients surgery was performed subsequently in an individual therapeutic approach. Out of n = 5 patients receiving additional regional hyperthermia, n = 3 achieved PR or SD. This single-centre experience does also not support the promising phase Ib/II results for olaratumab/doxorubicin in STS. However, our findings do not preclude that olaratumab combination therapy could be valuable in a neoadjuvant setting. This warrants further exploration also taking into account the heterogeneous nature of STS.
Sections du résumé
BACKGROUND
BACKGROUND
The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, recently the phase III ANNOUNCE trial could not confirm the additional value of olaratumab in this context.
METHODS
METHODS
Here, in a retrospective analysis we share our single-centre experience with olaratumab/doxorubicin in STS by including n = 32 patients treated with olaratumab/doxorubicin between 2016 and 2019.
RESULTS
RESULTS
Median progression-free survival (PFS) in the overall cohort was 3.1 months (range 0.6-16.2). A response [complete remission (CR), partial remission (PR) or stable disease (SD)] was seen in n = 11 (34%) cases, whereas n = 21 (66%) patients showed progressive disease (PD). In n = 9 patients surgery was performed subsequently in an individual therapeutic approach. Out of n = 5 patients receiving additional regional hyperthermia, n = 3 achieved PR or SD.
CONCLUSIONS
CONCLUSIONS
This single-centre experience does also not support the promising phase Ib/II results for olaratumab/doxorubicin in STS. However, our findings do not preclude that olaratumab combination therapy could be valuable in a neoadjuvant setting. This warrants further exploration also taking into account the heterogeneous nature of STS.
Identifiants
pubmed: 31996176
doi: 10.1186/s12885-020-6551-y
pii: 10.1186/s12885-020-6551-y
pmc: PMC6988236
doi:
Substances chimiques
Antibodies, Monoclonal
0
Doxorubicin
80168379AG
olaratumab
TT6HN20MVF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68Références
Sarcoma. 2018 Apr 4;2018:5671926
pubmed: 29849478
BMC Cancer. 2018 Dec 27;18(1):1292
pubmed: 30591028
Mayo Clin Proc. 2006 Sep;81(9):1241-57
pubmed: 16970222
Crit Rev Oncol Hematol. 2017 Oct;118:1-6
pubmed: 28917265
Eur J Cancer. 2018 Mar;92:33-39
pubmed: 29413687
Int J Hyperthermia. 2018;35(1):1-9
pubmed: 30300018
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269
pubmed: 30285214
Eur J Cancer. 2019 Jan;107:186-195
pubmed: 30573277
Am Soc Clin Oncol Educ Book. 2017;37:505-511
pubmed: 28561693
Handb Exp Pharmacol. 2012;(214):411-42
pubmed: 23027461
Cancer Cell. 2009 Jan 6;15(1):21-34
pubmed: 19111878
Lancet. 2016 Jul 30;388(10043):488-97
pubmed: 27291997
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
Wien Klin Wochenschr. 2019 Oct 16;:null
pubmed: 31620878
Mol Cancer Ther. 2005 Mar;4(3):369-79
pubmed: 15767546
Cancer Sci. 2014 Jul;105(7):862-9
pubmed: 24816152
Fibrogenesis Tissue Repair. 2011 Mar 01;4(1):8
pubmed: 21362163
JAMA Oncol. 2018 Apr 1;4(4):483-492
pubmed: 29450452
EMBO J. 2004 Jul 21;23(14):2800-10
pubmed: 15229650
Int J Cancer. 2017 Nov 15;141(10):1942-1949
pubmed: 28599355
Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604
pubmed: 24452395
EBioMedicine. 2019 Feb;40:224-230
pubmed: 30711517